Crispr Therapeutics shares tumble after significant earnings miss
On Tuesday, Palantir Technologies Inc . (NASDAQ:PLTR) shares soared in after-hours trading, following the company’s announcement of revenue and operating income that exceeded market expectations. Despite this, William Blair maintained an Underperform rating on the stock. Palantir’s financial outlook for 2025 anticipates revenues of $3.75 billion, which is above the consensus estimate of $3.51 billion but falls $750 million short of the $4.5 billion target previously mentioned by CEO Alex Karp during the earnings call on August 8, 2022. According to InvestingPro data, the company maintains impressive gross profit margins of 81.1% and has shown strong revenue growth of 24.5% over the last twelve months.
Typically, missing a three-year revenue projection by such a significant margin would negatively impact a company’s stock price. However, Palantir’s shares have defied this expectation, trading nearly ten times higher, with InvestingPro showing a remarkable 392% return over the past year. The company’s Foundry and Gotham software platforms are gaining considerable traction in the market, which may contribute to the stock’s resilience. InvestingPro analysis indicates the company’s overall financial health score is "GREAT," with particularly strong momentum and cash flow metrics.
Despite Palantir’s current success, William Blair expressed concerns over the company’s valuation. With a market capitalization around $190 billion, Palantir’s valuation stands at a premium of over $100 billion compared to its peers with similar fundamentals. The firm reiterated its Underperform rating, citing the potential for a repeat of the valuation multiple compression experienced in 2021 and 2022.
The analyst highlighted several factors that could potentially drive Palantir’s stock higher. These include the market momentum, investor optimism surrounding the new Trump administration, and the impact of artificial intelligence on Palantir’s operations. Nevertheless, the firm’s stance remains cautious due to the high valuation and past market trends.
In other recent news, Palantir Technologies has seen a flurry of activity from analysts. Wedbush raised their price target for the company to $120, citing impressive earnings and optimistic 2025 guidance. Similarly, BofA Securities increased their target to $125, shifting their valuation focus to a long-term outlook. HSBC also lifted their price target from $38 to $96, following the company’s robust Q1 results and full-year guidance for 2025. Mizuho (NYSE:MFG) Securities adjusted their outlook as well, raising the price target to $80, while maintaining an underperform rating. Finally, RBC raised its price target to $40, but retained an underperform rating.
These adjustments follow Palantir’s strong financial performance, with notable year-over-year revenue growth and a significant contract secured with the U.S. Army, valued at approximately $400.7 million. Despite the positive financial performance and raised price targets, most firms maintained a neutral rating on the stock, indicating a cautious stance on its current valuation. These recent developments underscore the dynamic performance and growth prospects of Palantir Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.